Regulation of human protein kinase-like protein
AssigneeBayer HealthCare LLC
InventorAlex Smolyar
Life of this patent
Estimating the term…
Abstract
Reagents that regulate human protein kinase-like protein and reagents which bind to human protein kinase-like gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, CNS disorders, COPD, obesity, diabetes, and cardiovascular disorders.
Claims71
An isolated polynucleotide being selected from the group consisting of:
- a) a polynucleotide encoding a proteine kinase-like protein polypeptide comprising an amino acid sequence selected form the group consisting of:
- amino acid sequences which are at least about 35% identical to the amino acid sequence shown in SEQ ID NO:
- 2;
- the amino acid sequence shown in SEQ ID NO:
- 2;
- amino acid sequences which are at least about 35% identical to the amino acid sequence shown in SEQ ID NO:
- 9;
- and
- the amino acid sequence shown in SEQ ID NO:
- 9.
- b) a polynucleotide comprising the sequence of SEQ ID NOS:
- 1;
- 8 or 10.
- c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b) and encodes a proteine kinase-like protein polypeptide;
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code and encodes a proteine kinase-like protein polypeptide;
- and
- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d) and encodes a proteine kinase-like protein polypeptide.
A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NOS:2 or 9.
An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NOS:2 or 9.
A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NOS:2 or 9.
A purified polypeptide comprising the amino acid sequence shown in SEQ ID NOS:2 or 9.
A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NOS:2 or 9.
A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NOS:2 or 9, comprising the steps of:
- culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed;
- and
- isolating the polypeptide.
A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NOS:2 or 9, comprising the steps of:
- hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NOS:1, 8 or 10 to nucleic acid material of a biological sample, thereby forming a hybridization complex;
- and
- detecting the hybridization complex.
A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NOS:2 or 9, comprising the steps of:
- contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex;
- and
- detecting the reagent-polypeptide complex.
A method of screening for agents which can modulate the activity of a human proteine kinase-like protein, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 35% identical to the amino acid sequence shown in SEQ ID NOS:2 or 9 and (2) the amino acid sequence shown in SEQ ID NOS:2 or 9;
- and
- detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the human proteine kinase-like protein.
A method of screening for agents which modulate an activity of a human proteine kinase-like protein, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 35% identical to the amino acid sequence shown in SEQ ID NOS:2 or 9 and (2) the amino acid sequence shown in SEQ ID NOS:2 or 9;
- and
- detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human proteine kinase-like protein, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human proteine kinase-like protein.
A method of screening for agents which modulate an activity of a human proteine kinase-like protein, comprising the steps of:
- contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NOS:1, 8 or 10;
- and
- detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human proteine kinase-like protein.
A method of reducing activity of a human proteine kinase-like protein, comprising the step of:
- contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NOS:1, 8 or 10, whereby the activity of a human proteine kinase-like protein is reduced.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NOS 2 or 9;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NOS:1, 8 or 10;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NOS:2 or 9;
- and
- a pharmaceutically acceptable carrier.
A method of treating a proteine kinase-like protein dysfunction related disease, wherein the disease is selected from cancer, a CNS disorder, COPD, obesity, diabetes, or a cardiovascular disorder comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human proteine kinase-like protein, whereby symptoms of the proteine kinase-like protein disfunction related disease are ameliorated.
Dependencies are inferred from the claim text.